CSL 689

Drug Profile

CSL 689

Alternative Names: CSL-689; rVIIa-FP

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B; Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Haemophilia A; Haemophilia B

Most Recent Events

  • 23 Apr 2018 CSL Behring terminates a phase II/III trial in Haemophilia A and Haemophilia B in Georgia, Italy, South Africa, Ukraine, UK, Malaysia, Germany, Russia, Thailand and Spain due to business decision (NCT02484638)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Oct 2016 CSL Behring completes a phase-I clinical trial in Haemophilia A and Haemophilia B in Netherlands and Norway (IV) (NCT02470871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top